This brand name is authorized in United States
The drug ANDEXXA contains one active pharmaceutical ingredient (API):
1
Andexanet alfa
UNII BI009E452R - ANDEXANET ALFA
|
Andexanet alfa is a recombinant form of human FXa protein that has been modified to lack FXa enzymatic activity. Andexanet alfa is a specific reversal agent for FXa inhibitors. The predominant mechanism of action is the binding and sequestration of the FXa inhibitor. In addition, andexanet alfa has been observed to bind to, and inhibit tissue factor pathway inhibitor (TFPI). Inhibition of TFPI activity can increase tissue factor-initiated thrombin generation inducing a pro-coagulant effect. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
ANDEXXA Powder for solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
V03AB38 | V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AB Antidotes | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: US | FDA, National Drug Code | Identifier(s): 69853-0101, 69853-0102 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.